Merck + Co., Inc.

Guy H Harris

Deborah L Zink

Suzanne M Mandala

Robert A Giacobbe

James E Curotto

Gerald F Bills

Henry Joshua

Isabel Martin

Jon David Polishook

Rosemary A Thornton

E Tracy Jones

Angeles Cabello

Otto D Hensens

Richard L Monaghan

Janet C Onishi

Fernando Pelaez

Michel M Chartrain

Anne W Dombrowski

Ali Shafiee

John R Thompson

Maria T Diez

Yu L Kong

Brian Heimbuch

Gregory L Helms

Walter Rozdilsky

Maria S Meinz

Stanley L Streicher

Myra B Kurtz

Richard K Jansson

Michael G Sturr

Teresa D Matas

Wendy H Clapp

Jennifer Nielsen-Kahn

Fernando Pelaez Perez

Angeles Cabello Arroyo

Francisca Vicente Perez

Bruce W Burgess

Janet M Sigmund

Mark Rattray

Joan A Lasota

S Dreikorn

Marie Williams

Sarah J Driekorn

Wendy H Clapp-Shapiro

Mark J Rosenbach

11-hydroxysordarin, biotransformation product of a fermentation with sordarin and Actinomyces spp., (Merck Culture Collection MA7235) ATCC No. 202103 is an antifungal agent. This compound may be useful in the treatment of diseases caused by fungal pathogens such as

11-hydroxysordarin and a process for producing it using actinomyces SSP

Biotransformation products of a fermentation with Streptomyces sp., (Merck Culture Collection MA7165) ATCC No. 55946 are potent antifungal agents. These products may be useful in the treatment of diseases caused by fungal pathogens such as Candida sp. and Cryptococcus neoformans.

Microbial transformation products with antifungal properties

There is disclosed a novel compound having the formula ##STR1## which exhibits antifungal activity.

Antifungal agent from sporomiella minimoides

Antifungal agent

There are disclosed novel compounds having the formula ##STR1## which exhibit antifungal activity.

Antifungal agents

A compound having the formula ##STR1## which is useful as an antifungal agent and for the treatment and control of several agricultural phytopathogens, including Phytophthora infestans, is disclosed.

This invention relates to compounds of structural formula (I) isolated from an aerobic fermentation of Trichoderma viride MF5628, ATCC 74084: ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents. These compounds are also potent antifungal agents. Additionally, they inhibit farnesyl protein transferase and farnesylation of the oncogene protein Ras and are thus useful in treating cancer. This invention also relates to a process for obtaining compounds of structural formula (I).

Biologically active compounds isolated from aerobic fermentation of

An acyclic tricarboxylic compound has been isolated from a culture of MF5453. The compound and its derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.

Cholesterol lowering compounds

Compounds having the formula ##STR1## wherein R and R.sup.1 may be H or COCH.sub.3 provided that when R.sup.1 is COCH.sub.3, R is COCH.sub.3 are described.

Antibiotic agents

A new Zaragozic acid analog has been isolated from a culture of MF5453. The compound and its derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.

Growing community of inventors

Cranford, NJ, United States of America

Guy H Harris